Literature DB >> 8757607

T cell recognition and tolerance of antibody diversity.

M C Eyerman1, X Zhang, L J Wysocki.   

Abstract

The capacity of B cells to self-present their Ab variable regions in the context of class II MHC structures suggests a potential regulatory problem. If T cells were able to recognize self-presented Ab, then T cell help might be delivered to B cells independently of a foreign carrier epitope, resulting in a chronic state of unregulated Ab synthesis. For this reason, we have proposed that T cells normally attain a state of tolerance to Ab V region diversity. Here, we tested this idea by performing direct immunizations with unmutated isologous mAb. We also identified and analyzed epitopes recognized by class II MHC-restricted T cell hybridomas that were originally generated against two physiologically mutated isologous mAb. Our results indicate that the class II MHC-restricted T cell repertoire is tolerant of germ-line-encoded Ab diversity and that the physiologic somatic hypermutation process creates immunogenic epitopes in Ab V regions, in some cases by producing class II MHC-binding peptides. In agreement with these findings, we found that germ-line-encoded Ab V regions are presented by endogenous splenic APC at a level that is physiologically significant.

Mesh:

Substances:

Year:  1996        PMID: 8757607

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Immunoglobulin subclass profiles of anti-idiotypic antibodies to GAD65Ab differ between type 1 diabetes patients and healthy individuals.

Authors:  S Oak; J Radtke; C Törn; M Landin-Olsson; C S Hampe
Journal:  Scand J Immunol       Date:  2011-10       Impact factor: 3.487

Review 2.  Protective role of anti-idiotypic antibodies in autoimmunity--lessons for type 1 diabetes.

Authors:  Christiane S Hampe
Journal:  Autoimmunity       Date:  2012-02-23       Impact factor: 2.815

3.  Immunoglobulin class switching appears to be regulated by B-cell antigen receptor-specific T-cell action.

Authors:  Hans Lange; Oliver Hecht; Michael Zemlin; Ahmad Trad; Radu I Tanasa; Harry W Schroeder; Hilmar Lemke
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

4.  Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes".

Authors:  Anne S De Groot; Leonard Moise; Julie A McMurry; Erik Wambre; Laurence Van Overtvelt; Philippe Moingeon; David W Scott; William Martin
Journal:  Blood       Date:  2008-07-25       Impact factor: 22.113

5.  Self-tolerance checkpoints in CD4 T cells specific for a peptide derived from the B cell antigen receptor.

Authors:  Thiago Detanico; Ryan A Heiser; Katja Aviszus; Cristina Bonorino; Lawrence J Wysocki
Journal:  J Immunol       Date:  2011-05-27       Impact factor: 5.422

6.  Aborted germinal center reactions and B cell memory by follicular T cells specific for a B cell receptor V region peptide.

Authors:  Ryan A Heiser; Christopher M Snyder; James St Clair; Lawrence J Wysocki
Journal:  J Immunol       Date:  2011-05-27       Impact factor: 5.422

7.  The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.

Authors:  Fiona A Harding; Marcia M Stickler; Jennifer Razo; Robert B DuBridge
Journal:  MAbs       Date:  2010-05-01       Impact factor: 5.857

Review 8.  Somatic mutagenesis in autoimmunity.

Authors:  Thiago Detanico; James B St Clair; Katja Aviszus; Greg Kirchenbaum; Wenzhong Guo; Lawrence J Wysocki
Journal:  Autoimmunity       Date:  2013-01-18       Impact factor: 2.815

9.  Tracking early autoimmune disease by bioluminescent imaging of NF-kappaB activation reveals pathology in multiple organ systems.

Authors:  Michael Zangani; Harald Carlsen; Anders Kielland; Audun Os; Harald Hauglin; Rune Blomhoff; Ludvig A Munthe; Bjarne Bogen
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

10.  Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells.

Authors:  Agnete B Fredriksen; Inger Sandlie; Bjarne Bogen
Journal:  Front Oncol       Date:  2012-10-30       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.